Abstract
Agitation is commonly seen in acute schizophrenic patients and core symptoms include a wide range of symptom. It requires rapid and effective treatment approaches in order to protect patient and caregiver from potential injury. Clinicians decision of pharmacological treatment should be individualized to the needs and circumstances of the patient. Benzodiazepines, typical antipsychotics, and combinations of typical antipsychotics and benzodiazepines have been widely used as treatment options. Atypical antipsychotics have clear advantages over the typical drugs as they generally show a much better safety and tolerability profile, particularly to EPS and related side effects, however clinical perception regarding efficacy in treating acutely agitated psychotic patient is controversial. New intramuscular atypical antipsychotic formulations offer evidence of being at least as effective as typical antipsychotics in controlling agitation. Therefore, they should be considered as first line therapy in agitated schizophrenic patients.
Keywords: atypical antipsychotics, intramuscular, schizophrenia, agitation
Current Pharmaceutical Design
Title: Pharmacological Management of Acutely Agitated Schizophrenic Patients
Volume: 11 Issue: 19
Author(s): L. San, B. Arranz and R. Escobar
Affiliation:
Keywords: atypical antipsychotics, intramuscular, schizophrenia, agitation
Abstract: Agitation is commonly seen in acute schizophrenic patients and core symptoms include a wide range of symptom. It requires rapid and effective treatment approaches in order to protect patient and caregiver from potential injury. Clinicians decision of pharmacological treatment should be individualized to the needs and circumstances of the patient. Benzodiazepines, typical antipsychotics, and combinations of typical antipsychotics and benzodiazepines have been widely used as treatment options. Atypical antipsychotics have clear advantages over the typical drugs as they generally show a much better safety and tolerability profile, particularly to EPS and related side effects, however clinical perception regarding efficacy in treating acutely agitated psychotic patient is controversial. New intramuscular atypical antipsychotic formulations offer evidence of being at least as effective as typical antipsychotics in controlling agitation. Therefore, they should be considered as first line therapy in agitated schizophrenic patients.
Export Options
About this article
Cite this article as:
San L., Arranz B. and Escobar R., Pharmacological Management of Acutely Agitated Schizophrenic Patients, Current Pharmaceutical Design 2005; 11 (19) . https://dx.doi.org/10.2174/1381612054367472
DOI https://dx.doi.org/10.2174/1381612054367472 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Visualization of DNA Double-Strand Break Repair: From Molecules to Cells
Current Medical Imaging Purine Nucleoside Phosphorylase: A Potential Target for the Development of Drugs to Treat T-Cell- and Apicomplexan Parasite-Mediated Diseases
Current Drug Targets Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications
Current Drug Safety Recent Progress on Development of TiO2 Thin Film Photocatalysts for Pollutant Removal
Recent Patents on Materials Science Nucleic Acids Electro-transfer: From Bench to Bedside
Current Drug Metabolism Molecular Imaging and Targeted Drug Delivery Using Albumin-Based Nanoparticles
Current Pharmaceutical Design Recent Developments in Deception Research
Current Psychiatry Reviews Antioxidant Properties of Melatonin and its Potential Action in Diseases
Current Topics in Medicinal Chemistry Cholesterol, Lipids, Amyloid Beta, and Alzheimers
Current Alzheimer Research Biomaterial and Mesenchymal Stem Cell for Articular Cartilage Reconstruction
Current Stem Cell Research & Therapy The Role of N-Methyl-D-Aspartate Receptor - Mediated Neurotransmission in Attention Deficit (Hyperactivity) Disorder (ADHD/ADD)
Current Psychopharmacology Molecular Genetic of Human Male Infertility: From Genes to New Therapeutic Perspectives
Current Pharmaceutical Design Mechanistic Aspects of Peptide-Membrane Interactions Determined by Optical, Dielectric and Piezoelectric Techniques: An Overview
Current Protein & Peptide Science The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Conference Report: Summary Report of the International Association of Neurorestoratology VII Conference: Regulations, Ethics, Science, and the Need of Patients Care in Neurorestoratology
CNS & Neurological Disorders - Drug Targets Targeting of NMDA Receptors in the Treatment of Major Depression
Current Pharmaceutical Design Trends in Patents of Enzymatic Biomarkers for Early Detection of Bacteria
Recent Patents on Biomarkers Dopamine Receptor Pharmacology: Interactions with Serotonin Receptors and Significance for the Aetiology and Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets The Clinical Development of γ-Hydroxybutyrate (GHB)
Current Drug Safety